** Eli Lilly LLY.N on Thursday downplayed CVS Health's CVS.N decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement
** CVS said it would drop coverage from July 1, but keep reimbursing for rival GLP-1 weight-loss drug Wegovy after negotiating a more favorable price from Novo Nordisk NOVOb.CO
WEIGHT LOSS MARKET HOLDING UP
** BofA Global Research ("buy," PO: $1000) says the CVS news does not mark a major, new negative trend, instead, it reflects "the reality that no company ever has all payers locked up"
** J.P.Morgan ("overweight," PT: $1100) says the CVS update to potentially only impact a small portion of LLY's Zepbound business
** Brokerage adds, "LLY to continue to see share gains relative to Wegovy in the broader obesity space as well as growth for the obesity market to remain healthy as a whole"
** Morgan Stanley ("overweight," PT: $1133) says in addition to Zepbound, LLY's drug pipeline under development like an oral GLP-1 medication, Orforglipron will strengthen co's position within the future obesity market
** Bernstein ("outperform," PT: $1100) says Novo and Lilly's battle is adding meaningful price pressure across incretin drugs
(Reporting by Kanchana Chakravarty in Bengaluru)
((Kanchana.Chakravarty@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.